Clinical trials: Daratumumab
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received…
- Trial name
- CEVOLUTION (NCT07555938)
- Testing
- Cevostamab, Pomalidomide, Dexamethasone
- Where
- 93 sites in United States, Australia and 16 more
- Volunteers
- 380 people
- Sponsor
- Hoffmann-La Roche
Aplastic Anemia, Platelet Transfusion Refractoriness
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
This is a phase 1, prospective, single-arm, open-label study. The aim of this study is to evaluate the transfusion responses of platelet increment by using Daratumumab among aplastic anemia patients with platelet transfusion…
- Trial name
- NCT05832216
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma Stage I
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation
The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo.
- Trial name
- MAXDARA (NCT03792620)
- Testing
- Cyclo Thal Dex Daratumumab
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis.
- Conditions
- Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Trial name
- NCT03283917
- Testing
- Daratumumab, Dexamethasone, Ixazomib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone…
- Trial name
- POM MM 014 (NCT01946477)
- Testing
- Pomalidomide, Dexamethasone, Daratumumab
- Where
- 49 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Celgene
Relapsed Refractory Multiple Myeloma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab…
- Trial name
- DURGA-4 (NCT07391657)
- Testing
- AZD0120, Daratumumab, Carfilzomib
- Where
- 143 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- AstraZeneca
Relapsed or Refractory Multiple Myeloma
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT03837509
- Testing
- INCB001158, Daratumumab SC
- Where
- 29 sites in United States, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
A Study of Daratumumab
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies…
- Trial name
- NCT05438043
- Testing
- Daratumumab, Carfilzomib, Dexamethasone
- Where
- 92 sites in United States, Belgium and 15 more
- Volunteers
- 213 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.
- Trial name
- REBUILD (NCT03475628)
- Testing
- Daratumumab
- Where
- Greece
- Volunteers
- 57 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma, Myeloma
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Newly diagnosed Multiple Myeloma patients who are ineligible for a transplant have inferior outcomes to that of the transplant population.
- Trial name
- NCT03695744
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 2 sites in Singapore
- Volunteers
- 27 people
- Sponsor
- Singapore General Hospital
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 27 sites in United States, Japan and 3 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone.
- Trial name
- NCT03290950
- Testing
- daratumumab, carfilzomib, lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment.
- Trial name
- aMMbition (NCT06577025)
- Testing
- Cilta-cel, Talquetamab, Daratumumab
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Multiple myeloma (MM) is the second most common hematological disease in Denmark with an incidence of approximately 350 diagnosed cases per year.
- Trial name
- NCT05306587
- Testing
- Darzalex
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Thomas Lund
Plasma Cell Myeloma, Secondary Amyloidosis
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
- Trial name
- NCT03346135
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
AL Amyloidosis
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis.
- Trial name
- NCT05898646
- Testing
- Bone Marrow Aspiration, Daratumumab, Echocardiography Test
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available or available through another protocol for subjects with…
- Trial name
- NCT02477891
- Testing
- Daratumumab
- Where
- 79 sites in United States, Brazil and 4 more
- Sponsor
- Janssen Research & Development, LLC
Relapse and / or Refractory Myeloma
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. A number of new drugs have been approved for the treatment of relapse myeloma in the last couple of years…
- Trial name
- NCT03143036
- Testing
- Daratumumab, thalidomide and dexamethasone
- Where
- 5 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 100 people
- Sponsor
- National University Hospital, Singapore
Autoimmune Disorders
Daratumumab in Primary Antiphospholipid Syndrome
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS).
- Trial name
- DARE-APS (NCT05671757)
- Testing
- Daratumumab
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)